Redhill Biopharma Ltd. (RDHL) Stock Price

RDHLStock

$0.66−49.92%52W

Market Cap$4.02M

P/E—

PEG Ratio—

Div yield—

Beta4.90

RDHL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-45.16%

Price vs S&P 500 (4W)0.12%

VGM Score43.56

Book Value / Share (Quarterly)$0.00

P/TBV (Annual)4.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-83.34%

Cash Flow / Share (Quarterly)$-0.00

Price vs S&P 500 (YTD)-48.65%

Gross Margin (TTM)60.41%

Net Profit Margin (TTM)-104.51%

EPS (TTM)$-0.00

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-0.00

Revenue Growth (5Y)-66.15%

EPS (Annual)$0.00

ROI (Annual)-8.04%

Gross Margin (Annual)60.31%

Net Profit Margin (5Y Avg)-23.30%

Cash / Share (Quarterly)$0.00

Revenue Growth QoQ (YoY)-96.44%

ROA (Last FY)-1.69%

Revenue Growth TTM (YoY)-58.88%

EBITD / Share (TTM)$-0.00

ROE (5Y Avg)-114.16%

Operating Margin (TTM)-282.25%

Cash Flow / Share (Annual)$-0.00

P/B Ratio0.90x

P/B Ratio (Quarterly)1.10x

Net Income / Employee (Annual)$-12,300

EV / Revenue (TTM)0.21x

Net Interest Coverage (TTM)4.20x

ROA (TTM)-20.87%

EV / EBITDA (TTM)0.19x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)0.34x

Quick Ratio (Quarterly)0.21x

3-Month Avg Trading Volume0.16M

52-Week Price Return-49.92%

Revenue / Employee (TTM)$124,700

Tangible BV / Share (Quarterly)$0.01

P/S Ratio (Annual)13.39x

Asset Turnover (Annual)0.01x

52-Week High$2.79

Operating Margin (5Y Avg)-522.77%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-84.38%

Tangible BV CAGR (5Y)13.88%

26-Week Price Return-33.23%

Quick Ratio (Annual)0.21x

13-Week Price Return-33.90%

Total Debt / Equity (Annual)0.25x

Current Ratio (Quarterly)0.34x

Enterprise Value$930,000

Revenue / Share Growth (5Y)-49.45%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-77.68%

Revenue / Employee (Annual)$8,200

Inventory Turnover (Annual)0.79x

Pretax Margin (Annual)-2825.17%

Cash / Share (Annual)$0.00

3-Month Return Std Dev81.06%

Gross Margin (5Y Avg)50.01%

Net Income / Employee (TTM)$-130,300

ROE (Last FY)-10.05%

Net Interest Coverage (Annual)-46.25x

EPS Basic Excl Extra (Annual)$0.00

Receivables Turnover (TTM)3.33x

EV / Free Cash Flow (TTM)-0.02x

Total Debt / Equity (Quarterly)0.25x

EPS Incl Extra (TTM)$-0.00

Receivables Turnover (Annual)0.22x

ROI (TTM)-8.04%

P/S Ratio (TTM)0.88x

Pretax Margin (5Y Avg)-558.33%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.01

Price vs S&P 500 (52W)-68.48%

Year-to-Date Return-35.83%

5-Day Price Return9.22%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)-8.56%

Net Profit Margin (Annual)-150.00%

Month-to-Date Return1.69%

Cash Flow / Share (TTM)$31.18

EBITD / Share (Annual)$-0.00

Operating Margin (Annual)-2776.92%

LT Debt / Equity (Annual)9.39x

ROI (5Y Avg)97.34%

LT Debt / Equity (Quarterly)9.39x

EPS Basic Excl Extra (TTM)$-0.00

P/TBV (Quarterly)5.75x

P/B Ratio (Annual)1.10x

Inventory Turnover (TTM)1.38x

Pretax Margin (TTM)-279.79%

Book Value / Share (Annual)$0.00

Price vs S&P 500 (13W)-35.85%

Beta4.90x

Revenue / Share (TTM)$0.00

ROE (TTM)-10.05%

52-Week Low$0.57

vGradeA

gGradeF

mGradeD

vgmGradeC

RDHL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2022	Apr 28, 2023	$0.00	$0.00	+0.00%(+$0.00)
Q3 2022	Nov 29, 2022	-$10.00	-$60.00	-500.00%(-$50.00)
Q2 2022	Nov 7, 2022	-$10.00	-$20.00	-100.00%(-$10.00)
Q1 2022	Jun 23, 2022	-$30.00	-$30.00	+0.00%(+$0.00)

RDHL Analyst Recommendations

Dec 2024

Jan 2025

Feb 2025

Mar 2025

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
RDHLRedhill Biopharma Ltd.	A	F	D	$0.66
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Redhill Biopharma Ltd.

Redhill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal diseases, with commercialized products Talicia and Aemcolo available in the U.S. market. The company maintains a clinical-stage pipeline of five therapeutic candidates, including Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, primarily in clinical development.